Baidu
map

抗胆碱能药物噻托溴铵治疗中度至重度哮喘存在争议

2013-07-02 David 医学界

  近期,发表于Journal of Allergy and Clinical Immunolog上的一篇综述总结了长效抗胆碱能药物在哮喘治疗中的应用。作者提到,使用抗胆碱药物维持治疗慢性阻塞性肺疾病(COPD)是公认的。然而使用抗胆碱能药物治疗中度至重度哮喘仍然是一个有争议的点。   早期病例报告和小规模的研究评估使用抗胆碱能药物噻托溴铵在哮喘

  近期,发表于Journal of Allergy and Clinical Immunolog上的一篇综述总结了长效抗胆碱能药物在哮喘治疗中的应用。作者提到,使用抗胆碱药物维持治疗慢性阻塞性肺疾病(COPD)是公认的。然而使用抗胆碱能药物治疗中度至重度哮喘仍然是一个有争议的点。

  早期病例报告和小规模的研究评估使用抗胆碱能药物噻托溴铵在哮喘维持治疗中的作用。包括最近几次使用噻托溴铵作为辅助药物治疗哮喘的临床试验为长效抗胆碱能药物在哮喘治疗中的应用提供更多的证据。噻托溴铵的使用被证明是优于双倍剂量的吸入皮质类固醇的,而且采用呼气峰流速(PEF)的变化来评估疗效显示噻托溴铵比安慰剂更有效。

  作者最后总结:使用长效抗胆碱能药物噻托溴铵作为哮喘为维持期的治疗措施,已经证明是有效的,特别是在部分有中度至严重哮喘且使用ICS和LABA联合治疗的患者中。但是,还需要进一步研究以更好地定义不同表型的患者能否使用噻托溴铵。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1796895, encodeId=21381e9689508, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 15 17:02:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663675, encodeId=8f0d16636e55c, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Tue Oct 15 03:02:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527373, encodeId=b299152e37310, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546074, encodeId=07c415460e468, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620005, encodeId=ef9a162000551, content=<a href='/topic/show?id=2d77403e06e' target=_blank style='color:#2F92EE;'>#噻托溴铵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40370, encryptionId=2d77403e06e, topicName=噻托溴铵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6920056137, createdName=12498fa0m17暂无昵称, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1796895, encodeId=21381e9689508, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 15 17:02:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663675, encodeId=8f0d16636e55c, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Tue Oct 15 03:02:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527373, encodeId=b299152e37310, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546074, encodeId=07c415460e468, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620005, encodeId=ef9a162000551, content=<a href='/topic/show?id=2d77403e06e' target=_blank style='color:#2F92EE;'>#噻托溴铵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40370, encryptionId=2d77403e06e, topicName=噻托溴铵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6920056137, createdName=12498fa0m17暂无昵称, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1796895, encodeId=21381e9689508, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 15 17:02:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663675, encodeId=8f0d16636e55c, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Tue Oct 15 03:02:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527373, encodeId=b299152e37310, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546074, encodeId=07c415460e468, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620005, encodeId=ef9a162000551, content=<a href='/topic/show?id=2d77403e06e' target=_blank style='color:#2F92EE;'>#噻托溴铵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40370, encryptionId=2d77403e06e, topicName=噻托溴铵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6920056137, createdName=12498fa0m17暂无昵称, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=)]
    2013-07-03 grace5704
  4. [GetPortalCommentsPageByObjectIdResponse(id=1796895, encodeId=21381e9689508, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 15 17:02:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663675, encodeId=8f0d16636e55c, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Tue Oct 15 03:02:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527373, encodeId=b299152e37310, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546074, encodeId=07c415460e468, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620005, encodeId=ef9a162000551, content=<a href='/topic/show?id=2d77403e06e' target=_blank style='color:#2F92EE;'>#噻托溴铵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40370, encryptionId=2d77403e06e, topicName=噻托溴铵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6920056137, createdName=12498fa0m17暂无昵称, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1796895, encodeId=21381e9689508, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Aug 15 17:02:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663675, encodeId=8f0d16636e55c, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Tue Oct 15 03:02:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527373, encodeId=b299152e37310, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546074, encodeId=07c415460e468, content=<a href='/topic/show?id=a31055665d9' target=_blank style='color:#2F92EE;'>#抗胆碱能药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55665, encryptionId=a31055665d9, topicName=抗胆碱能药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83e413868282, createdName=ms1490123962508630, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620005, encodeId=ef9a162000551, content=<a href='/topic/show?id=2d77403e06e' target=_blank style='color:#2F92EE;'>#噻托溴铵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40370, encryptionId=2d77403e06e, topicName=噻托溴铵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6920056137, createdName=12498fa0m17暂无昵称, createdTime=Wed Jul 03 15:02:00 CST 2013, time=2013-07-03, status=1, ipAttribution=)]

相关资讯

Diabetes Care:糖尿病合并COPD患者应谨慎使用皮质激素类药物

经不同剂量皮质激素分层,因糖尿病并发症住院累积发生率 为了确定采用皮质激素治疗的糖尿病合并慢性阻塞性肺病(COPD)患者糖尿病并发症风险是否呈剂量依赖性增加。来自南澳大利亚大学药学和医学科学院药品使用质量和药学研究中心的Gillian E. Caughey博士等人进行了一项研究,研究发现,糖尿病合并COPD患者使用高剂量皮质激素时糖尿病相关住院风险明显增高。研究结果在线发表于2013年6月4日美

Baidu
map
Baidu
map
Baidu
map